Venrock Healthcare Capital Partners III, L.P., 10% Owner at KalVista Pharmaceuticals, Inc. (KALV), bought 103,008 shares at $12.98 ($1.4M) on 2024-01-26, disclosed to the SEC on 2024-01-29.
Open-market purchase of $1.4M KALV by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.73 | 7,030 | $89K | 6.2% |
| 2 | $12.73 | 7,030 | $89K | 6.2% |
| 3 | $12.98 | 4,174 | $54K | 3.8% |
| 4 | $12.98 | 4,174 | $54K | 3.8% |
| 5 | $14.22 | 80,600 | $1.1M | 80.0% |
| Total | $13.92 avg | 103,008 |
| $1.4M |
| 100% |
| Filing → |
| KALV | BUY | 2024-02-01 | $2.5M | — | Filing → |
| KALV | BUY | 2024-01-10 | $2.8M | — | Filing → |
| UMRX | BUY | 2020-08-18 | $1.4M | — | Filing → |